Showing 61-70 of 184 results for "".
Golden Achievement: Dr. Michael Gold on Lifetime Award at CSF 2016
https://practicaldermatology.com/topics/practice-management/golden-achievement-dr-michael-gold-on-lifetime-award-at-csf-2016/18712/Michael H. Gold, MD was recognized December 2016 at the Cosmetic Surgery Forum in Las Vegas with the Lifetime Contribution to Aesthetics Award by CSF Founder Joel Schlessinger, MD. Speaking about the award, Dr. Gold shares his perspective as a global educator and practitioner (Dr. Gold cofounded theHispanic Home Remedies (remedios caseros) in the Management of Dermatologic Disease: A Focused Review
https://practicaldermatology.com/columns/clinical-focus-1/hispanic-home-remedies-iremedios-caserosi-in-the-management-of-dermatologic-disease-a-focused-review/23718/Chamomile, aloe vera, green tea, honey, and apple cider vinegar are popular remedios caseros.Protecting Assets in a Divorce
https://practicaldermatology.com/topics/practice-management/protecting-assets-in-a-divorce/18771/Statistics show that half of marriages end in divorce. Financial consequences can be significant. OJM Group principal David Mandell, JD, MBA, discusses how physicians can protect their assets in the pre-marital and the marital stages in the event of a divorce. Always contact local counsel before taAsset Protection 101: What Every Dermatologist Should Know
https://practicaldermatology.com/topics/practice-management/asset-protection-101-what-every-dermatologist-should-know/18875/OJM Group principal David Mandell, JD, MBA, reviews the importance of protecting assets for physicians, introduces the asset protection "sliding scale" and outlines basic tools for protecting personal and practice assets.To obtain a free copy of "Wealth Protection Planning for Dermatologists" visit- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications
- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous
- Medicis Announces Winners of First Annual I Acanya Succeed Scholarship Programhttps://practicaldermatology.com/news/20131007-medicis_announces_winners_of_first_annual_i_acanya_succeed_scholarship_program/2459442/Medics, a division of Valeant Pharmaceuticals North America LLC, recently announced the winners of its first I Acanya Succeed scholarship program, an education-based initiative that provides scholarships to college students who h
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a
- Phase I Trial for Implantable Melanoma Vaccine Beginshttps://practicaldermatology.com/news/20130910-phase_i_trial_for_implantable_melanoma_vaccine_begins/2459466/
- Biosimilar Update: Dr. Reddy’s Completes Phase I Study of Proposed Tocilizumab Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-dr-reddys-completes-phase-i-study-of-proposed-tocilizumab-biosimilar/2461765/Dr. Reddy’s Laboratories’ tocilizumab biosimilar candidate, DRL_TC, met its primary and secondary endpoints in a Phase I study. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogeni